MaxCyte, Inc. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $4.1 million, 83% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19
|
5
|
5
|
5
|
5
|
6
|
6
|
6
|
6
|
| Product |
16
-26.6%
share 84.2%
|
4
-22.2%
share 83.0%
|
4
-31.5%
share 80.8%
|
4
-28.4%
share 86.8%
|
4
-23.9%
share 85.9%
|
5
share 90.5%
|
5
share 92.6%
|
6
share 95.7%
|
5
share 92.6%
|
| Assay And Other Service Revenue |
2
share 12.3%
|
1
+88.1%
share 11.8%
|
0
+21.4%
share 10.7%
|
1
share 12.7%
|
1
+56.2%
share 14.1%
|
0
share 5.3%
|
0
share 6.9%
|
—
|
0
share 7.4%
|
| License |
1
-87.9%
share 3.5%
|
0
+4.1%
share 5.2%
|
0
+1166.7%
share 8.4%
|
0
-99.1%
share 0.5%
|
2
-12.8%
share 48.4%
|
0
share 4.2%
|
0
share 0.5%
|
3
share 43.6%
|
3
share 45.5%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- MXCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1287098
- Former names
- MAXCYTE INC (until Sep 18, 2008)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.